INTRODUCTION
Despite more than 50 years of effective antitubercular drugs, tuberculosis (TB) eradication remains elusive (Sacchettini et al., 2008) due to the complexity of curative treatment regimens (Connolly et al., 2007; Donald and McIlleron, 2009 ). Long-term therapy is required to prevent relapses with genetically drugsensitive bacilli that become transiently resistant in the host, a phenomenon called tolerance. The best-case regimen of six months was made possible by drug combinations that presumably reduce the tolerant population (Donald and McIlleron, 2009 ). This so-called ''short course therapy'' represented a major advance, as prior regimens lasted 12-18 months. However, adherence to 6 months of multidrug treatment is difficult, leading to relapses that perpetuate the epidemic and fuel the development of genetic resistance (Sacchettini et al., 2008) . Thus, an urgent goal of antitubercular drug discovery is to overcome tolerance (Connolly et al., 2007; Sacchettini et al., 2008) . Several new drugs are in development (Sacchettini et al., 2008 ), yet most lack this key treatment-shortening property. This failure highlights a poor understanding of TB tolerance mechanisms (Barry et al., 2009; Connolly et al., 2007; Sacchettini et al., 2008; Warner and Mizrahi, 2006) . Drug tolerance in TB is best contextualized to the in vivo lifestyle of mycobacteria. Mycobacterium tuberculosis (Mtb) resides within complex immunological structures called granulomas, either within macrophages or extracellularly, in the necrotic core (caseum) (Figure S1 available online) (Barry et al., 2009; Connolly et al., 2007) . Multiple granuloma types, reflecting different levels of local disease activity, may coexist in a given patient ( Figure S1 ) (Barry et al., 2009; Canetti, 1955; Connolly et al., 2007; Rich, 1946) . A longstanding model is that tolerant bacteria are sequestered in a subset of granulomas wherein their replication and metabolism are uniformly slowed ( Figure S1 ) (Barry et al., 2009; Connolly et al., 2007) . Newer models posit that quiescent, drug-tolerant bacteria are present in all lesion types and may be induced by deterministic mechanisms that are responsive to stress (e.g., hypoxia) and/or the stochastic formation of persister cells, some of which may be nonculturable under standard laboratory conditions ( Figure S1 ) (Barry et (Table S1 ).
(A) Survival of uninfected (UN) larvae versus those infected with 800 Mm and immediately treated with RIF, MOX, EMB, INH, or left untreated (UNT). (Left) In the presence of 1% DMSO (see Figure S2A ). Survival of treated infected larvae was significantly different from UNT larvae for all drugs (Table S2) Sacchettini et al., 2008; Warner and Mizrahi, 2006) . However, all tolerance models and consequently drug discovery efforts are centered on the assumption that slowed growth and/ or metabolic quiescence is the primary mediator of tolerance.
In this study, we demonstrate that growing mycobacteria develop multidrug tolerance soon after they infect macrophages. This understanding was gained by a two-pronged approach. First, we used zebrafish larvae infected with Mycobacterium marinum (Mm) to spatially and temporally characterize the responses of individual animals to frontline antitubercular drugs. Mm infections feature drug tolerance and require long-term treatment in both humans and fish (Aubry et al., 2002; Decostere et al., 2004) . Using the larval model, we discovered that tolerant bacteria arise within individual macrophages soon after infection and are then expanded and disseminated by tuberculous granulomas. Guided by these findings, we used cultured macrophage infection models combined with bacterial efflux pump mutants and pharmacological inhibitors to identify both a mechanism and a therapy for macrophage-induced tolerance in TB.
RESULTS

A Zebrafish Larval Model for In Vivo Characterization of Antitubercular Drug Activity
To assess antitubercular drug activity in the model, we infected larvae intravenously with GFP-expressing Mm and maintained them in the presence of antitubercular drugs. Concentrations that represented multiples of the in vitro minimum inhibitory concentration (MIC) for Mm were used, and the drug-supplemented water was changed daily (Table S1 , Figures S2A-S2E , and Experimental Procedures). We established minimal isoniazid (INH), rifampicin (RIF), ethambutol (EMB), and moxifloxacin (MOX) concentrations that were nontoxic and normalized host survival when administered within 1 day postinfection (dpi), which we term the minimum effective concentration (MEC) (Figure 1A,  Table S1, and Table S2 ). Bacterial burdens of infected larvae can be assessed visually by fluorescence microscopy or quantitatively by larval lysis and enumeration of bacterial colony-forming units (CFU). To facilitate rapid, serial quantification of bacterial burden, we developed software that enumerates fluorescent pixels in images of infected larvae, or fluorescent pixel count (FPC), and showed it to be an accurate predictor of bacterial burden ( Figure S3 and Experimental Procedures). Increased survival was associated with lower bacterial burdens at 4 days posttreatment (dpt), as judged by fluorescence microscopy, and was confirmed quantitatively by FPC and CFU analyses ( Figures 1A-1F , Figure S3 , and Table S2 ). Findings that were consistent with human TB data were also obtained with streptomycin (STM, Figures S2C-S2E ), which has resurged as a cornerstone of treatment for extremely drug-resistant (XDR) TB (Donald and McIlleron, 2009) . In summary, clinically relevant antitubercular drugs were efficacious in the zebrafish infection model, with the expected exception of pyrazinamide, to which Mm is innately resistant (Figures S2F and S2G) .
To further probe the model's relevance to human TB, we used the MECs as starting points from which to examine drug potency and dose-dependent activity. In human pulmonary TB studies, the early bactericidal activity (EBA) of antitubercular drugs, defined as their ability to reduce sputum bacterial counts in pulmonary TB patients over the first several days, has been useful to guide drug dosing (Donald and Diacon, 2008; Jindani et al., 2003) . Each drug has distinctive EBA characteristics. For RIF, doses greater than the currently used therapeutic dose increase the EBA, raising the question of whether higher doses would have greater efficacy (Donald and Diacon, 2008) . In the larvae, treatment with the RIF MEC caused a 1.2 log 10 reduction in bacterial burden, whereas treatment with twice the MEC caused an additional 1.2 log 10 reduction despite increased toxicity ( Figures 1E-1G ). We similarly observed dose-dependent activity for MOX: stepwise increases in concentration produced greater diminutions in bacterial burdens ( Figure S2H ). In contrast to RIF, INH EBA does not increase when the conventional dose is doubled. We also observed no further reduction in bacterial counts at double the INH MEC (data not shown). Further, stepwise 2-fold reductions from the conventional dose continue to show activity in human TB, with a graded EBA decrease down to 1/16th the therapeutic dose (Donald and Diacon, 2008) . Similarly, we found a graded concentration-dependent bactericidal activity down to 1/24th the MEC ( Figures 1H and 1I ) and a therapeutic benefit at 1/5th the MEC ( Figure 1J ).
Finally, because drug-resistant TB is an increasing problem (Sacchettini et al., 2008) , we asked whether the model could differentiate Mm strains with altered drug susceptibility. INH resistance is usually the first to occur in human TB and often the first step in the progression to XDR TB (Donald and McIlleron, 2009) . INH is a prodrug activated by the bacterial catalase KatG, and the vast majority of INH-resistant clinical Mtb isolates have katG mutations (Sandgren et al., 2009 ). We identified a spontaneous INH-resistant Mm katG mutant with an in vitro INH MIC of 464 mM, 8-fold higher than for wild-type ( Figure 1K and Extended Experimental Procedures). The relative resistance of the Mm katG mutant was detectable in vivo: in larvae infected with wild-type Mm, maximal bacterial killing was observed at 290 mM, whereas an 8-fold higher concentration was ineffective against the katG mutant ( Figure 1L ). INH resistance was specific: EMB, which has a distinct target (Belanger et al., 1996) , showed similar efficacy against both strains ( Figure 1L ). In summary, the zebrafish larval model reliably replicates the activity of antitubercular compounds and their dosing characteristics in humans.
comparisons, with the exception of 12 versus 58 mM INH, which was not significant (p > 0.05). (J) Survival curve, n = 6 larvae per group. p = 0.0018, log-rank test for trend comparing all curves; p = 0.0010 for comparison of UNT versus 58 mM or UNT versus 290 mM. 
Drug Tolerance Occurs Prior to Granuloma Formation
Our observation that residual cultivatable bacteria persisted 4 dpt, despite initiating treatment within a day of infection when the bacteria were in individual macrophages ( Figures 1B-1D) , suggested the early presence of drug-tolerant bacteria, prior to granuloma formation. We pursued this observation in detail for INH because its tolerance in human TB has been studied extensively (Donald and Diacon, 2008; Donald and McIlleron, 2009; Jindani et al., 2003) . We confirmed that the residual bacteria were tolerant, rather than genetically resistant, to INH: the INH susceptibility of individual bacilli recovered from six treated larvae (10.3 ± 1.2 CFU per larva) was unchanged from the parental strain.
INH tolerance is seen in human EBA studies in which monotherapy produces biphasic killing. The majority of the bacteria are killed with 2 days of treatment, after which the rate of killing drops, leaving a population of drug-tolerant bacteria 14 dpt (Figure 2A) (Donald and Diacon, 2008; Jindani et al., 2003) . We conducted an EBA-like study in the larvae, starting treatment after granulomas had formed, at 3 dpi. Serial quantitative tracking of infection by fluorescence microscopy revealed that INH killing kinetics mirror those observed in human EBA studies ( Figures  2A-2C) .
By tracking individual animals, we determined the location of the persistent bacteria ( Figure 2B ). Several infected macrophages had very little diminution in fluorescence, suggesting that they contained tolerant bacteria, and their varying positions on consecutive days suggested their continued movement during treatment. There were also residual infected macrophages ( Figure 2B , arrowhead) from granulomas that had dissolved with treatment ( Figure 2B , arrow). Thus, tolerant bacteria were present both in individual macrophages and in granuloma macrophages.
In human TB, the addition of RIF to INH-containing regimens has shortened time to sterilization and thus treatment length. This is reflected in EBA studies in which RIF is not rapidly bactericidal on its own and the additional activity of the INH-RIF combination is seen only in the slower phase of killing, when INH-tolerant bacteria are implicated (Figure 2A ) (Donald and Diacon, 2008; Jindani et al., 2003) . Therefore, RIF's treatmentshortening effect is attributed to its capacity to reduce INH-tolerant bacteria (Donald and McIlleron, 2009) . Reminiscent of the human data, RIF in the larvae was not rapidly bactericidal on its own ( Figure 2D ), yet it increased INH efficacy in the slow phase of its EBA curve ( Figure 2E ). Residual bacteria persisted after combination therapy, albeit fewer than with INH monotherapy ( Figure 2F ). In sum, the model demonstrates drug tolerance akin to that seen in human TB and the well-known synergistic effect of RIF in reducing tolerance. Furthermore, it reveals tolerant bacteria within individual macrophages at the earliest stages of infection.
Drug-Tolerant Bacteria Are Expanded and Disseminated by Granuloma Formation
All models of TB tolerance invoke metabolically quiescent bacteria (Barry et al., 2009; Connolly et al., 2007; Sacchettini et al., 2008; Warner and Mizrahi, 2006 ). Yet during human TB treatment, individual lesions can expand, or new ones appear at distant sites, despite overall clinical improvement and reduction in lesion size and number (Akira et al., 2000; Barry et al., 2009; Bobrowitz, 1980; Canetti, 1955) . Importantly, bacteria from new lesions are drug sensitive, and the patients are ultimately cured with no change in therapy (reviewed in Akira et al., 2000) . These observations are consistent with an uneven distribution of drug-tolerant bacteria that expand locally or after dissemination. Indeed, even before the advent of effective TB therapy, it was appreciated that, within a given patient, some lesions resolve while others worsen, suggesting distinct local host responses in the course of natural infection (Canetti, 1955; Rich, 1946) .
We wondered whether the drug-tolerant bacteria that we had observed within scattered macrophages are the ones that are then amplified and disseminated by mechanisms of granuloma formation (Davis and Ramakrishnan, 2009 ). However, we first had to determine whether our model recapitulated the differential progression of natural infection. We found that, in the first week of infection, some granulomas progressed while others resolved ( Figure 3A ). Lesions in the head region (containing the organs) were more likely to progress, whereas those in the tail region (primarily muscle) were more likely to resolve ( Figures  3B and 3C ). The effect was even more striking at later developmental stages (days 7 to 11), when organogenesis is more advanced ( Figure 3C ). By 1 month, granulomas were exclusively within organs ( Figure 3D and 3E), reminiscent of the observation that human TB seldom involves muscle (Rich, 1946) .
Next, to study the effect of drug treatment on individual lesions, we infected larvae with a range of inocula to achieve varying infection burdens ( Figure 3F ) and then began INH treatment for half of the larvae. We quantified and spatially localized infection in each animal at the start of treatment and 3 days later by fluorescence microscopy. As expected, untreated larvae demonstrated an increase in bacterial burden (+0.2176 log 10 FPC, p = 0.0008, Student's t test), whereas treatment reduced the bacterial burden (À1.001 log 10 FPC).
Spatial monitoring of the untreated larvae confirmed the expected differential progression of lesions. Ten of the 12 treated larvae had a reduction in bacterial burdens ranging from 32.3% to 99.7% ( Figures 3F and 3G ). We found local ''nonresponsiveness'' among the responding larvae, analogous to that observed in humans ( Figures 3G-3I ). For example, fish 11 (Figures 3G and 3H) had an overall 32.3% reduction in bacterial burden, yet two individual infected macrophages expanded into two infected cells and a granuloma and multiple new foci appeared. New foci developed even in animals with an overall >90% reduction in bacterial burdens (e.g., fish 5, Figures 3G  and 3I ).
Finally, we determined whether new infection foci resulted from the egress of macrophages (containing tolerant bacteria) from existing granulomas, a phenomenon that we have documented during untreated infection (Davis and Ramakrishnan, 2009) . We infected larvae with bacteria expressing the fluorescent reporter Kaede that changes from green to red upon photoactivation (Davis and Ramakrishnan, 2009 ). We selectively photoactivated the largest granuloma and immediately began INH treatment (Figure 3J, left) . We then assessed whether macrophages harboring the photoactivated bacteria left granulomas after initiating treatment. Within 24 hr, three infected macrophages had left the granuloma and dispersed far from the initial site ( Figure 3J , right). Importantly, the original granuloma had shrunk substantially, showing its overall response to therapy, consistent with the human data (Bobrowitz, 1980) . The bacteria within the departed macrophages were both red and green fluorescent, suggesting that they were synthesizing new Kaede protein and thus metabolically active, again consistent with the human data in which the new foci had viable bacteria that were then able to expand. In summary, as is the case in human TB, individual lesions in Mm-infected zebrafish larvae respond variably to treatment, and dissemination occurs during effective therapy. The detailed temporal monitoring possible in this model suggests a mechanism for these longstanding observations in humans: drug treatment selects for tolerant bacteria residing within individual macrophages, which can expand into granulomas by recruiting new macrophages and/or migrate to disseminate infection.
Macrophage Residence Induces Drug Tolerance in Mm and Mtb
The drug-tolerant bacteria observed within larval macrophages can be explained by three nonmutually exclusive mechanisms: (1) pre-existing drug-tolerant persisters, (2) induction of tolerance upon exposure to the macrophage environment, and (3) induction of tolerance upon exposure to drug. Subtherapeutic concentrations of multiple drugs produce tolerance in actively growing Mtb cultures (de Steenwinkel et al., 2010; Morris et al., 2005; Viveiros et al., 2002) , and we found this to also be the case for Mm ( Figure S4A ). To probe the mechanism(s) of tolerance in the context of host infection, we examined the development of INH tolerance in larvae depleted of macrophages by antisense knockdown of the PU.1 myeloid transcription factor; in the absence of macrophages, the Mm grow extracellularly (Clay et al., 2007) . Wild-type and macrophage-depleted (PU.1) larvae were infected at 1 day postfertilization (dpf), and INH treatment was begun the following day. By 2 dpt, when INH tolerance is first apparent (Figure 2C ), wild-type larvae had 10.4% ± 2.9% of the bacteria in the untreated controls, whereas PU.1-depleted larvae had 3.4% ± 0.7%, a 3.1-fold reduction ( Figure 4A ). The improved relative efficacy of INH in the PU.1-deficient larvae was even greater at 4 dpt, with a 5.7-fold relative reduction (1.9% ± 0.4% residual bacteria in wild-type versus 0.3% ± 0.07%) ( Figure 4A ). These data suggested that the tolerant bacterial population was enriched by macrophage residence.
To determine the mechanism of this macrophage-dependent tolerance, we turned to a cell culture infection model using J774A.1 mouse or THP-1 human macrophage cell lines (Volkman et al., 2004) . Cells infected with Mm for either 2 or 96 hr were treated with 174 mM INH (3-fold the in vitro MIC) for an additional 48 hr and then lysed to obtain intracellular bacterial counts. After 2 hr of macrophage infection, 7.6% ± 0.8% Mm survived the subsequent 48 hr of INH treatment, whereas after a 96 hr infection period, 49.5% ± 8.1% survived treatment, representing a 6.5-fold increase in persisting bacteria ( Figures 4B and 4C ). There was no additional killing with 10-fold increased INH (1740 mM) ( Figure 4C ). The INH MIC for the bacteria recovered at 96 hr was unchanged from the parental strain, confirming that they had not acquired genetic resistance.
Our findings suggested that intramacrophage residence induces drug tolerance. Alternatively, drug activity could be limited intracellularly due to the residence of a bacterial subpopulation in a protected niche or to drug modification by the host cell. To differentiate between these possibilities, bacteria were grown in macrophages for 2 or 96 hr, released from the infected macrophages, and then incubated in bacterial growth medium with and without drugs for an additional 48 hr prior to plating. Even with direct exposure to 174 mM INH, the proportion of tolerant bacteria was > 200-fold higher at 96 hr postinfection (hpi) than after 2 hpi ( Figure 4D and Table S3 ). Macrophage-conditioned Mm also developed tolerance to RIF with a 20.6-fold increase in survival and to MOX with a 4.8-fold increase in survival ( Figure 4D and Table S3 ). Dilution of the macrophage lysates prior to exposure to antibiotics did not affect the proportion of tolerant organisms ( Figure S4B ), excluding the possibility that tolerance was simply due to increased bacterial density at 96 hr ( Figure 4B ). Finally, we found that Mtb also develops macrophage-induced drug tolerance: 96 hr versus 2 hr infection yielded > 2.3-fold increase in INH survival and > 2.8-fold increase in RIF survival ( Figure 4E and Table S3 ). Thus, macrophage residence rapidly induces Mm and Mtb to become tolerant to multiple drug classes.
Drug Tolerance Is Associated with a Replicating Intracellular Population
Current models invoke host-induced bacteriostasis as a mechanism for drug tolerance during infection. Indeed, both Mtb and Mm exhibit drug tolerance under conditions of slowed growth (C) Enumeration of expanding and contracting granulomas over time. Differential region-specific outcomes of granulomas were statistically significant for changes occurring between days 7 and 11 (p = 0.0022), but not for changes occurring between days 4 and 7 (p = 0.2360, Fisher's exact test). (D and E) Hematoxylin and eosin staining showing Mm in caseating granulomas in a 33-day-old fish that was infected at 1 dpf. Red and black arrows indicate granulomas in pronephros and liver, respectively. gl, gill; sb, swim bladder; sm, somite. Scale bar, 300 mm. Higher magnification of granulomas in boxed inset of (D) is shown on bottom-right of (E). Scale bar, 50 mm. (F-I) Larvae infected with varying Mm inocula for 4 days were then treated with 290 mM INH or left untreated for an additional 3 days. Larvae were imaged at 4 and 7 dpi (0 and 3 dpt). in vitro ( Figure S4C ) (Paramasivan et al., 2005) . Moreover, the net growth of Mm in macrophages appeared to decline slightly between 48 and 96 hr ( Figure 4B ), raising the possibility that tolerance might result from macrophage-induced bacteriostasis. However, both our zebrafish studies and prior human clinical data showed that bacteria expand and disseminate in vivo in the face of drug treatment. Thus, even if tolerance is initially associated with nongrowing persisters, they must somehow then retain the tolerance phenotype upon resuming growth.
To probe the replicative state of the tolerant bacteria, we manipulated intracellular growth by treating infected macrophages with dexamethasone (DEX), a broad-spectrum antiinflammatory agent that increases net intracellular bacteria (Rook et al., 1987) . DEX treatment resulted in a 2.1-fold increase in intracellular Mm at 96 hr that was accompanied by a 1.4-fold and 2.1-fold increase in the proportion of bacteria tolerant to INH and RIF, respectively (Figures 5A and 5B and Table S4 ). These experiments revealed that tolerance is not diminished by increased bacterial growth and suggested, rather, that it is enhanced in growing intracellular bacteria.
We then directly compared the numbers of drug-tolerant bacteria in nongrowing and growing intracellular populations. We transformed Mm with the unstable plasmid pBP10 that is lost at a constant rate from dividing, but not nondividing, mycobacteria ( Figure S5 ) (Gill et al., 2009) . Using Mm/pBP10, we showed the rate of plasmid loss per generation to be unchanged under different growth conditions ( Figure S5 and Supplemental Experimental Procedures). We next used Mm/pBP10 to examine bacterial growth in macrophages. The generation time of the intracellular population was not decreased over the 96 hr assay period ( Figure 5C and Figure S5) . Furthermore, the apparent slowing of growth between 48 and 96 hr ( Figure 4B ) was, in fact, due to a large increase in bacterial death, which overshadowed a more modest increase in growth rate in this time period ( Figure S5E ).
We then compared the proportion of drug-tolerant bacteria in the population that had retained the plasmid (Kan R ; i.e., bacteria that had not yet replicated and daughter cells that had retained the plasmid upon replication) to that in the population that had lost the plasmid (Kan S ; i.e., completed at least one round of (D) Mm were used to infect THP-1 macrophages for 2 or 96 hr prior to being released by macrophage lysis. CFU were enumerated at the time of release and again following 48 hr exposure to 174 mM INH, 1.21 mM RIF, 7.48 mM MOX, or left untreated. For the purpose of display, values below the limit of detection (0.08%, dashed line) were arbitrarily set to 0.074%. p values were determined using Student's t test (RIF and MOX) or the Mann-Whitney rank test (INH). (E) Mtb strain H37Rv was used to infect J774A.1 macrophages that were grown and treated as described for (D) except that the concentration of INH was 4.4 mM, reflecting the greater inherent susceptibility of this organism to INH. For the purpose of display, values below the limit of detection (0.6%, dashed line) were arbitrarily set to 0.57%. p values were determined using the Mann-Whitney rank test. In all panels, error bars represent SEM. replication). Drug-tolerant bacteria were enriched in the Kan S population: 3.5-fold for INH, 7.6-fold for RIF, and 7.6-fold for MOX ( Figure 5D and Table S4 ). Together, these results suggested that drug tolerance was not associated with macrophage-induced bacteriostasis but, rather, that it was enhanced in the growing intracellular population.
Macrophage-Induced Bacterial Efflux Pumps Mediate Drug Tolerance
One explanation for the multiclass drug tolerance that we observed is a reduction in steady-state intrabacterial drug concentration, which could be achieved by decreased drug entry and/or increased efflux. The induction of efflux pumps causes single or multidrug resistance in many bacteria, including Mtb (De Rossi et al., 2006; Li and Nikaido, 2009; Louw et al., 2009 ), so we investigated their potential role in macrophageinduced tolerance. Mtb and Mm encode numerous efflux pumps that can mediate resistance to antitubercular drugs when overexpressed (Li and Nikaido, 2009) . Efflux pump activity has been invoked to explain multiple aspects of drug resistance in mycobacteria: (1) intrinsic resistance, (2) acquired multidrug resistance, and (3) tolerance induced by antimicrobial exposure (De Rossi et al., 2006; Gupta et al., 2010; Louw et al., 2009; Morris et al., 2005; Viveiros et al., 2002) . Moreover, several mycobacterial efflux pumps and their regulators are induced during macrophage infection (Fontá n et al., 2008; Morris et al., 2005; Nguyen and Thompson, 2006; Ramó n-García et al., 2009; Rohde et al., 2007; Schnappinger et al., 2003; Zä hner et al., 2010) . Finally, efflux pump inhibitors enhance the activity of certain drugs on drug-resistant Mtb; these include the currently approved pump inhibitors verapamil (VER), reserpine (RES), and thioridazine (Li and Nikaido, 2009) .
To determine whether bacterial efflux pumps mediated macrophage-induced drug tolerance, we added subinhibitory VER and RES in conjunction with antibiotics to macrophagereleased Mm and found that tolerance was reduced (Figures  6A and 6B and Table S5 ). VER produced a 15.6-fold reduction in INH survival and a 9.2-fold reduction in RIF survival; RES produced a 4.8-fold reduction in INH survival and a 7.9-fold reduction in RIF survival. These effects were specific to macrophage-induced tolerance: VER did not reduce stationary phase-induced tolerance to INH or RIF ( Figure S6A ).
In Mtb, VER reduced tolerance to RIF, but not to INH ( Figure 6C and Table S5 ). RIF survival was reduced by 1.4-fold and 1.9-fold, In all panels, error bars represent SEM. p values were determined using Student's t test.
respectively, in bacteria grown intracellularly for 96 and 144 hr prior to challenge. This result suggests that Mtb possesses VER-resistant pumps that are distinct from those used by Mm. Consistent with this idea, INH exposure induces transcription of more efflux pumps than does RIF in MDR-TB (Gupta et al., 2010) . Moreover, drug-induced INH tolerance in Mtb is sensitive to RES, but not to VER (Colangeli et al., 2005; Viveiros et al., 2002) .
Our data suggested that distinct efflux pumps mediate INH and RIF tolerance in Mtb. The Mtb Rv1258c efflux pump is transcriptionally induced upon: (1) macrophage infection (Morris et al., 2005; Schnappinger et al., 2003) and (2) exposure to subinhibitory concentrations of RIF, but not INH, in an Mtb isolate that is resistant to both drugs (Siddiqi et al., 2004) . Hypothesizing that Rv1258c mediates macrophage-induced RIF tolerance, we tested two Mtb strains with distinct transposon insertions in Rv1258c. After 96 hr of macrophage residence, both mutants retained INH, but lost RIF, tolerance ( Figure 6D and Table S5 ). Indeed, they became hypersusceptible to RIF: whereas the wild-type had a 3.0-fold increase in tolerance, the mutants had 2.5-and 2.0-fold reductions in tolerance. Moreover, the mutants were compromised for intramacrophage growth ( Figure 6E ), suggesting that this efflux pump is required for both intracellular growth and RIF tolerance.
To confirm that the loss of tolerance in the Rv1258c mutants was not simply a function of intracellular growth attenuation, we tested two additional mutants with macrophage growth defects: Mm mutants lacking the RD1/ESX-1 secretion system or the cell surface/secreted Erp protein retained macrophageinducible antibiotic tolerance ( Figures S6B and S6C) . The Erp mutant developed RIF tolerance despite being RIF hypersusceptible at baseline (Cosma et al., 2006b ). This would suggest that efflux pump induction due to intracellular residence allowed the bacteria to extrude sufficient RIF to become more resistant than at baseline, despite growth attenuation. In contrast, the Rv1258c-deficient bacteria become hypersusceptible to RIF because their intracellular damage is coupled to an inability to expel RIF.
Finally, we showed that the Mtb Rv1258c mutants retained stationary phase-induced RIF tolerance, again showing specificity of this efflux pump in mediating macrophage-induced tolerance ( Figure S6D ). In sum, these results suggest that bacterial efflux pumps that are induced upon macrophage infection to promote intracellular bacterial growth also serve to mediate drug tolerance. This mechanistic understanding explains the enrichment of tolerant bacteria in the growing intracellular population.
VER Reduces Intracellular Mm Growth and Tolerance
If VER reduces tolerance by inhibiting bacterial efflux pumps induced upon intracellular residence, it should reduce tolerance when administered directly to infected macrophages. It should also inhibit intracellular growth, as suggested by the Rv1258c mutants. Indeed, efflux pump and potassium transport inhibitors have been found to promote intracellular killing of multidrugresistant Mtb (Amaral et al., 2007) . We similarly found that incubation of Mm-infected macrophages with VER reduced intracellular bacterial growth at concentrations that did not impact bacteria in axenic culture ( Figure 6F and Figure S6A ). Incubation of infected macrophages with VER also inhibited tolerance (Figure 6G) . The 96 hr Mm-infected macrophages were treated with INH alone or INH and VER for an additional 48 hr before lysis and bacterial enumeration; the addition of VER reduced tolerance by 2.0-fold ( Figure 6G and Table S5 ). Finally, when added to a synergistic combination of INH and RIF, VER further reduced tolerance by 2.2-fold ( Figure 6G and Table S5 ), suggesting the potential of VER to increase the efficacy of existing treatment regimens. Taken together, the finding that mutations in Rv1258c and treatment with the efflux pump inhibitor VER lead to the same two phenotypes (growth attenuation and loss of tolerance) indicates that efflux pumps are required for both processes. Moreover, the observation that VER treatment phenocopies the Rv1258c mutation argues that it is the loss of Rv1258c function in the mutants, rather than polar effects on downstream genes, that is responsible for the observed phenotypes.
Macrophage-Induced Tolerance Persists after Bacteria Are Rendered Extracellular Both the zebrafish larval model and the human EBA studies reveal the existence of tolerant bacteria. However, in contrast to the intracellular bacteria present in the larvae, the tolerant bacteria assessed in the human studies are thought to be predominantly extracellular, residing within the necrotic cores of open cavitary lesions ( Figure S1 ). Necrosis results from death of the granuloma's macrophage core and is sustained by continued influx and lysis of infected and uninfected macrophages (Cosma et al., 2004; Dannenberg, 2003) . Thus, for macrophage-induced tolerance to play a significant role in human cavitary TB, it must persist after the bacteria are rendered extracellular by macrophage lysis. To test this model, we lysed Mm out of macrophages and monitored the proportion of tolerant organisms over time. Mm retained tolerance for at least 120 hr after macrophage release despite continued replication in the lysate ( Figure S7A and S7B). Whether tolerance is retained due to slow turnover of the efflux pump or persistence of the original macrophage stimulus in the lysates remains to be determined. Regardless of the mechanism, these findings argue that extracellular bacteria in cavitary TB may be rendered tolerant by prior growth in macrophages.
DISCUSSION
Drug tolerance presents a significant challenge to the eradication of TB. Here, we exploit complementary infection models to demonstrate that macrophages and granulomas both play a role in the induction and expansion of drug-tolerant bacteria.
The zebrafish larval model has enabled reassessment of fundamental dogmas about the role of macrophages and granulomas in TB pathogenesis (Davis and Ramakrishnan, 2009; Tobin and Ramakrishnan, 2008; Tobin et al., 2010; Volkman et al., 2010) . These studies found that, rather than serving as strictly host-protective structures, granulomas are co-opted by mycobacteria for their expansion and dissemination. We now show that tolerant bacteria arising within individual macrophages similarly exploit granulomas for their amplification and dissemination during the course of drug treatment. This finding helps to explain decades-old observations that human TB lesions can expand, and new ones appear, in the face of overall clinical and radiological response (Akira et al., 2000; Bobrowitz, 1980; Canetti, 1955) .
The core finding of this study is that drug-tolerant bacteria originate in macrophages dependent on the activity of bacterial efflux pumps (Figure 7) . Within a few days of macrophage infection, a bacterial subpopulation arises that manifests tolerance to multiple drugs independent of drug exposure. The association between intramacrophage growth and drug tolerance suggests that a common mechanism promotes both. This is borne out by our finding that Rv1258c is required for both macrophage growth and intracellular RIF tolerance in Mtb. The activation of bacterial efflux pumps in response to membrane and oxidative stress and antimicrobial peptides in vitro (Morris et al., 2005; Nguyen and Thompson, 2006; Ramó n-García et al., 2009; Zä hner et al., 2010) suggests that their induction during intracellular residence may protect the bacteria from these same conditions in vivo. For example, efflux pumps mediate intrinsic resistance of Neisseria meningitidis to human antimicrobial peptides (Tzeng et al., 2005) . The finding that DEX-treated macrophages induce tolerance may shed some light on the intracellular stimuli involved. DEX treatment suppresses macrophage oxidative bursts while preserving antimicrobial peptide expression (Duits et al., 2001; Ehrchen et al., 2007) . Antimicrobial peptides, which are induced in Mtb-infected human macrophages and are required for macrophage antimycobacterial activity (Liu et al., 2007; Rivas-Santiago et al., 2008) , may mediate the induction of bacterial efflux pumps and thereby tolerance.
Our in vivo results show that tolerant bacteria arise within a subset of infected macrophages during treatment. This may be due to macrophage heterogeneity, again underscoring the complexity of the macrophage-Mycobacterium interface. Individual macrophages may cause distinct and/or differential induction of bacterial efflux pumps and, thus, variable tolerance within the bacterial population. Additionally, antibiotics have long been thought to act in co-operation with cellular host defenses, an idea further supported by the increasing recognition of the complex, multidimensional mechanisms of antibiotic activity (Kohanski et al., 2010) .
How do our findings relate to human clinical studies? Among the readily cultivable bacilli in the sputum of humans with active cavitary TB, two distinct populations have been described: drug susceptible and drug tolerant (Jindani et al., 2003) . The metabolic status of the tolerant population has been the source of much debate. Spurred by our discovery of early tolerance in zebrafish larvae, we revisited human EBA and radiological studies and realized that growing, tolerant populations must mediate the progression and expansion of tubercular lesions that occur in the face of treatment (Bobrowitz, 1980; Jindani et al., 2003) . The association between tolerance and intracellular growth in the zebrafish larval and macrophage models provides a mechanism for the earlier human studies. Further strengthening this link is our finding that tolerance persists for days after the bacteria are released from macrophages, suggesting that the bacteria present in the necrotic core of macrophage-lined cavities may utilize similar tolerance mechanisms.
Slowly growing bacteria that are not cultivable under standard conditions have also been observed in human sputum (Garton et al., 2008; Mukamolova et al., 2010) . These too appear to be drug tolerant, but their relative impact on treatment duration and clinical relapse is unclear (Mukamolova et al., 2010) . Importantly, tolerance models centered on nonreplicating bacteria do not account for the recent finding that diarylquinolones, which are equally bactericidal for exponentially growing and dormant bacteria in culture (Koul et al., 2008) , only shorten the time to cure from 6 months to 4 in the mouse model of TB, which features slowed bacterial growth (Ibrahim et al., 2009; Muñ ozElías et al., 2005) . Although this shortening may be extremely important clinically, it does not support the notion that tolerance, and thus the long duration required for therapy, is mediated solely by dormant bacterial populations. One possibility is that the growing, tolerant bacteria revealed in this work are responsible for the substantial residual tolerance observed after diarylquinolone-containing therapies. Nontolerant bacteria are phagocytosed by macrophages soon after infection wherein they induce efflux pumps to counter macrophage defenses. These efflux pumps render bacteria tolerant to multiple antitubercular drugs. The tolerant bacteria are associated with the growing population because of their enhanced ability to counter macrophage defenses. Antitubercular drug treatment spares tolerant bacteria, and the addition of efflux pump inhibitors reduces their numbers.
In summary, we have identified a population of drug-tolerant bacteria that are likely to be substantially present in TB patients as they are induced by macrophages, which host dynamic mycobacterial populations throughout infection. Current drug discovery efforts, with their emphasis on quiescent tolerant bacteria, fail to take into account the role of this population in tolerance. Our identification of pharmacological measures to reduce the numbers of growing tolerant bacteria suggests an approach to further shorten TB chemotherapy. Our finding that the same pump mediates both growth and tolerance suggests that the identification of more potent specific inhibitors with a dual bacterial killing mechanism is possible. Indeed, some are already being tested against Rv1258c . Ultimately, the best assessment of whether targeting these newly discovered tolerant bacteria is the key to truly short-course chemotherapy will come from clinical trials using efflux pump inhibitors like VER.
Finally, the tolerance mechanisms and counter strategies that we describe for mycobacteria may be relevant to other intracellular pathogens. Indeed, macrophage-induced tolerance to multiple drug classes is described for Legionella pneumophila, an agent of pneumonia (Barker et al., 1995) . Thus, our findings may have relevance for Legionella as well as other recalcitrant intracellular pathogens that produce serious and often relapsing infections in which tolerance is a barrier to therapy.
EXPERIMENTAL PROCEDURES
Bacterial Strains and Methods M. marinum strain M (ATCC BAA-535) and its fluorescent derivatives have been described (Cosma et al., 2006a; Davis and Ramakrishnan, 2009) . A spontaneous INH-resistant mutant identified in our laboratory (KA1) was found to have increased resistance to INH (MIC 64 mg/ml), and the katG locus was subsequently sequenced. Plasmid pBP10 (gift of D. Sherman, Seattle Biomed) was transformed into strain M to yield strain KA2, referred to in the text as Mm/pBP10. Mm were grown in standard media (see Extended Experimental Procedures) and prepared for experimental manipulations by growth to midlog phase, followed by passage through a sterile 5 mM filter to yield a single cell suspension. INH susceptibility of bacteria isolated from INH-treated larvae was verified by patching all outgrown colonies onto 7H10 agar containing 10, 20, and 40 mg/ml INH and comparing growth to that of the parental strain. The INH MIC of three colonies was confirmed to be identical to strain M.
Mtb strain H37Rv was from D. Sherman (Seattle Biomed). Mtb strains JHU1258c-715 and JHU1258c-833 (harboring transposon insertions at positions 715 and 833, respectively, in the Rv1258c ORF) and the wild-type parent strain CDC1551 were from W.R. Bishai and G. Lamichhane (Johns Hopkins University) (Lamichhane et al., 2003) . Mtb were grown to midlog phase in standard medium prior to infection.
Zebrafish Infections
Wild-type AB zebrafish were from our laboratory stock, and PU.1 morphant embryos have been described (Clay et al., 2007) . Larvae were infected via caudal vein injections at 36-48 hr postfertilization (Cosma et al., 2006a) and maintained as described for individual experiments with feeding instituted at day 14 dpf (Davis and Ramakrishnan, 2009 ).
Microscopy
Wide-field fluorescence microscopy was performed using a Nikon E600 equipped with a Nikon D-FL-E fluorescence unit with a 100 W Mercury lamp. Wide-field fluorescence images were captured using a CoolSnap HQ CCD camera (Photometrics) with MetaMorph 7.1 (Molecular Devices).
Fluorescent Pixel Count
Quantification of infection with fluorescent Mm using images of individual embryos was performed using custom-made MATLAB software developed in house. In brief, in each image, the number of pixels with a fluorescence intensity greater than the brightest pixel observed in images of control uninfected embryos is counted. This count represents the total fluorescent area (in pixels) for each infected larva.
Calculation of Early Bactericidal Activity FPC counts were log 10 transformed, and for each larva, the difference between each day's measurement and the initial burden was calculated. EBAs over defined intervals were calculated by taking the mean and SD of the D log 10 FPC values calculated for individual larvae.
Macrophage Growth and Infection J774A.1 and THP-1 macrophages were grown in DMEM and RPMI, respectively, supplemented with 10% FBS and 1% L-glutamine. THP-1 cells were differentiated with phorbol 12-myristate 13-acetate for 48 hr prior to infection. 1 3 10 5 J774A.1 or 5 3 10 5 THP-1 macrophages were infected at an MOI of 1.5 for 2-3 hr at 33 C (for Mm) or an MOI of 1 for 2-3 hr at 37 C (for Mtb). Cells were washed with medium and then 20 (for Mm) or 6 (for Mtb) mg/ml STM was added (t = 0) for the duration of the intracellular growth. Medium was changed daily. Macrophages were lysed with 0.1% Triton X-100 for intracellular growth quantization. To lyse macrophages and release bacteria for subsequent tolerance assessment, each well was first washed once with 1 3 PBS and once with diH 2 O, with the latter wash being removed immediately. Then, 200 ml of diH 2 0 was added and the cells incubated for 15 min to lyse macrophages. Finally, 800 ml of 1.253 concentrated 7H9 medium (see Extended Experimental Procedures) was added and the wells scraped gently with a pipette tip to release all macrophages. CFU were enumerated from triplicate wells on supplemented 7H10 agar. For determination of antibiotic killing, the percent survival was calculated by dividing the CFU for each well by the mean CFU present prior to treatment.
Statistics
Statistical analyses were performed using Prism 5.01 (GraphPad). For data sets requiring log 10 transformation prior to ANOVA, embryos with no detectable fluorescence above background, or with no detectable CFU were assigned a value of 0.9, with 1 being the limit of detection, prior to log 10 transformation. A Mann Whitney rank test was used when values in one group were all below the limit of detection. Posttest p values are as follows: *p < 0.05; **p < 0.01; ***p < 0.001. 
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